Prl 3 cdna expression vector

Manufactured by OriGene

Sourced in United States

The PRL-3 cDNA expression vector is a laboratory tool used for the controlled expression of the PRL-3 gene. It provides a means to study the properties and functions of the PRL-3 protein in experimental settings.

Automatically generated - may contain errors

Lab products found in correlation

Mirus transit lt1 reagent, by Mirus Bio (2 mentions)

3 protocols using prl 3 cdna expression vector

Synthesis and Expression of PRL-3

Check if the same lab product or an alternative is used in the 5 most similar protocols

AMPI-109 was synthesized as previously described [15 (link)]. PRL-3 cDNA expression vector was purchased from Origene (Cat. # SC308739).

Gari H.H., Gearheart C.M., Fosmire S., DeGala G.D., Fan Z., Torkko K.C., Edgerton S.M., Lucia M.S., Ray R., Thor A.D., Porter C.C, & Lambert J.R. (2016). Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers. Oncotarget, 7(13), 15757-15771.

+ Open protocol

+ Expand

PRL-3 Knockdown in Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

PRL-3 cDNA expression vector was purchased from Origene (Cat. # SC308739). Transfections were carried out using Mirus TransIT LT1 reagent according to manufacturer’s instructions (Mirus Bio). Individual pLKO.1 lentiviral shRNA clones were purchased from the University of Colorado Cancer Center Functional Genomics Shared Resource. The RNAi Consortium identifiers are: TRCN0000010661 (shPRL-3 #1), TRCN0000355597 (shPRL-3 #2), TRCN0000378843 (shMMP-10 #1), TRCN0000372935 (shMMP-10 #2). Transduced cells were selected in medium containing 2.5 μg/mL puromycin. Specificity of PRL-3 knock down was determined by qRT-PCR. Both PRL-3 shRNAs (#1 and #2) exerted specific knock down of PRL-3 and did not reduce RNA levels of either PRL-1 or PRL-2.

Gari H.H., DeGala G.D., Ray R., Lucia M.S, & Lambert J.R. (2016). PRL-3 Engages the Focal Adhesion Pathway in Triple-Negative Breast Cancer Cells to Alter Actin Structure and Substrate Adhesion Properties Critical for Cell Migration and Invasion. Cancer letters, 380(2), 505-512.

+ Open protocol

+ Expand

Genetic Manipulation of PRL-3 and Signaling Pathways

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

PRL-3 cDNA expression vector was purchased from Origene (Rockville, MD, USA; Cat. #SC308739). Transfections were carried out using Mirus TransIT LT1 reagent according to the manufacturer's instructions (Mirus Bio, Madison, WI, USA). Individual pLKO.1 lentiviral shRNA clones were obtained from the University of Colorado Cancer Center Functional Genomics Shared Resource. The RNAi Consortium identifiers are: TRCN0000010661 (shPRL-3 #1), TRCN0000355597 (shPRL-3 #2), TRCN0000014683 (shp65 #1), TRCN0000014684 (shp65 #2), TRCN0000359596 (shTNF-R1 #1) and TRCN0000359597 (shTNF-R1 #2). Transduced cells were selected in medium containing 2.5 ug/ml puromycin. PRL-3 shRNAs were previously validated.^{6 (link)}

Gari H.H., DeGala G.D., Lucia M.S, & Lambert J.R. (2016). Loss of the oncogenic phosphatase PRL-3 promotes a TNF-R1 feedback loop that mediates triple-negative breast cancer growth. Oncogenesis, 5(8), e255-.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!